Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.31 |
| ▸ | BRD4 | O60885 | 2/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NSD2 | O96028 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13511734 | 0.81 | MTNR1A (0.41) | MTNR1AMTNR1BPTPN11BRD4CREBBP | |
| SCHEMBL543260 | 0.76 | HTR2C (0.39) | MTNR1AMTNR1B | |
| SCHEMBL543395 | 0.76 | MTNR1A (0.36) | MTNR1AMTNR1B | |
| SCHEMBL15514759 | 0.74 | MAPT (0.37) | MTNR1AMTNR1BBRD4CREBBPKDM4E | |
| SCHEMBL31500716 | 0.73 | KDM4E (0.41) | MTNR1AMTNR1BKDM4ENSD2ALDH1A1 | |
| SCHEMBL21631668 | 0.73 | MET (0.35) | MTNR1AMTNR1BPTPN11KDM4ENSD2 | |
| SCHEMBL21631652 | 0.73 | PTPN11 (0.36) | PTPN11KDM4ENSD2ALDH1A1MAPT | |
| SCHEMBL31500719 | 0.73 | ALDH1A1 (0.33) | MTNR1AMTNR1BKDM4ENSD2ALDH1A1 | |
| SCHEMBL29303477 | 0.71 | MAT2A (0.33) | — | |
| SCHEMBL21631665 | 0.70 | NQO2 (0.42) | KDM4ENSD2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109900-A1 | AZABICYCLIC SHP2 INHIBITORS | PROMIDIS S.R.L. (IT) | 2024-04-04 | — | — | US | disclosed |
| EP-4288431-A1 | AZABICYCLIC SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2023-12-13 | — | — | EP | disclosed |
| WO-2022167682-A1 | AZABICYCLIC SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2022-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109900-A1 | AZABICYCLIC SHP2 INHIBITORS | PTPN22, PTPN2, PTPN5 | MTNR1A 3306/4885MTNR1B 2968/4885PTPN11 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.